A blog about what is new (and old) in the world of active implantable medical devices 

Facebook Twitter Gplus Flickr LinkedIn YouTube RSS
magnify
Home AIMD Business Boston Scientific’s Q3 2012 AIMD Results: CRM Dropped 6%, Neuromodulation Up 5%
formats

Boston Scientific’s Q3 2012 AIMD Results: CRM Dropped 6%, Neuromodulation Up 5%

Boston Scientific Logo

Today Boston Scientific reported its results for Q3 2012.  For its AIMD divisions:

Cardiac Rhythm Management sales dropped from $503M in Q3 of 2011 to $462M for this year (-8%), a 6% decrease on constant-currency basis.

Neuromodulation sales grew by 5% from $84M to $88M.

 
 Share on Facebook Share on Twitter Share on Reddit Share on LinkedIn
Comments Off on Boston Scientific’s Q3 2012 AIMD Results: CRM Dropped 6%, Neuromodulation Up 5%  comments